NASDAQ:OSMT - Osmotica Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.25
  • Forecasted Upside: 222.30 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.02 (-0.69%)

This chart shows the closing price for OSMT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Osmotica Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OSMT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OSMT

Analyst Price Target is $9.25
▲ +222.30% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Osmotica Pharmaceuticals in the last 3 months. The average price target is $9.25, with a high forecast of $11.00 and a low forecast of $8.00. The average price target represents a 222.30% upside from the last price of $2.87.

This chart shows the closing price for OSMT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Osmotica Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/2/2021Royal Bank of CanadaReiterated RatingBuyN/A
3/17/2021Royal Bank of CanadaLower Price TargetOutperform$12.00 ➝ $8.00Low
12/30/2020TruistLower Price Target$11.00 ➝ $8.00N/A
9/3/2020Wells Fargo & CompanyReiterated RatingHoldHigh
7/10/2020SunTrust BanksBoost Price TargetBuy$8.00 ➝ $11.00High
7/10/2020SVB LeerinkBoost Price TargetOutperform$8.00 ➝ $10.00High
7/9/2020Royal Bank of CanadaBoost Price Target$10.00 ➝ $12.00High
3/25/2020Royal Bank of CanadaReiterated RatingBuy$10.00High
3/23/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$4.00Low
3/18/2020SunTrust BanksInitiated CoverageBuy$8.00High
3/6/2020SVB LeerinkInitiated CoverageOutperform$10.00Low
8/12/2019Jefferies Financial GroupSet Price TargetBuy$10.00Medium
8/9/2019Wells Fargo & CompanyReiterated RatingBuyLow
6/11/2019BarclaysInitiated CoverageOverweight ➝ Overweight$11.00High
3/28/2019Wells Fargo & CompanySet Price TargetBuy$14.00High
11/14/2018BarclaysInitiated CoverageOverweightHigh
11/12/2018Jefferies Financial GroupInitiated CoverageBuy ➝ BuyHigh
11/12/2018Wells Fargo & CompanyInitiated CoverageOutperform ➝ Outperform$18.00High
11/12/2018Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$17.00High
(Data available from 6/21/2016 forward)
Osmotica Pharmaceuticals logo
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis; and OS870 which is in Phase I clinical trial for the treatment of neurodegenerative disorders. It also provides women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorders and social anxiety disorders; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; prescription prenatal vitamins for treating nutritional requirements during pregnancy; Lorzone, an immediate-release form of chlorzoxazone indicated for the treatment of acute musculoskeletal pain in conjunction with rest and physical therapy; ConZip, a tramadol hydrochloride for the management of pain; and nitrofurantoin for the treatment of urinary tract infections, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
Read More

Today's Range

Now: $2.87
Low: $2.78
High: $2.87

50 Day Range

MA: $3.02
Low: $2.88
High: $3.27

52 Week Range

Now: $2.87
Low: $2.85
High: $9.67


4,535 shs

Average Volume

320,713 shs

Market Capitalization

$179.62 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Osmotica Pharmaceuticals?

The following Wall Street research analysts have issued stock ratings on Osmotica Pharmaceuticals in the last twelve months: Royal Bank of Canada, SunTrust Banks, Inc., SVB Leerink LLC, Truist, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for OSMT.

What is the current price target for Osmotica Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for Osmotica Pharmaceuticals in the last year. Their average twelve-month price target is $9.25, suggesting a possible upside of 229.2%. SunTrust Banks, Inc. has the highest price target set, predicting OSMT will reach $11.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $8.00 for Osmotica Pharmaceuticals in the next year.
View the latest price targets for OSMT.

What is the current consensus analyst rating for Osmotica Pharmaceuticals?

Osmotica Pharmaceuticals currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OSMT will outperform the market and that investors should add to their positions of Osmotica Pharmaceuticals.
View the latest ratings for OSMT.

What other companies compete with Osmotica Pharmaceuticals?

How do I contact Osmotica Pharmaceuticals' investor relations team?

Osmotica Pharmaceuticals' physical mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company's listed phone number is 908-809-1300 and its investor relations email address is [email protected] The official website for Osmotica Pharmaceuticals is